ALV-100 for keeping weight off in adults with overweight or obesity
Tests ALV-100 in adults with overweight or obesity after earlier weight loss.
Plain-language title generated from the registry record
Registry title: Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Key facts
- Where
- Birmingham, Bradenton, Champaign, Doral, Farmington Hills, Gretna, Irving, Nashville, New York, Oceanside, Oklahoma City, Orlando, San Antonio, South Jordan, Sun City, Tempe, Tomball, Wilmington, and Woodstock, United StatesSee the 20 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07837973, who can take part
Where in United States
- University of Alabama BirminghamBirmingham, United StatesTaking people
- DM Clinical ResearchBradenton, United StatesTaking people
- Christie ClinicChampaign, United StatesTaking people
- DM Clinical ResearchDoral, United StatesTaking people
- Profound ResearchFarmington Hills, United StatesTaking people
- BRCR Global LouisianaGretna, United StatesTaking people
- DM Clinical ResearchIrving, United StatesTaking people
- AMR ClinicalNashville, United StatesTaking people
- ALSA Research-ManhattanNew York, United StatesTaking people
- Profound ResearchOceanside, United StatesTaking people
- Lynn Health Science InstituteOklahoma City, United StatesTaking people
- Clinical Neuroscience SolutionsOrlando, United StatesTaking people
- DM Clinical Research - Dominion Family HealthcareSan Antonio, United StatesTaking people
- Tekton ResearchSan Antonio, United StatesTaking people
- AMR ClinicalSouth Jordan, United StatesTaking people
- DM Clinical ResearchSun City, United StatesTaking people
- AMR ClinicalTempe, United StatesTaking people
- DM Clinical ResearchTomball, United StatesTaking people
- TMA HeadlandsWilmington, United StatesTaking people
- North Georgia Clinical ResearchWoodstock, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alveus Therapeutics, Inc.
- Trial code
- NCT07837973
- Record updated
- 26 October 2026
- Original description
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.Read full original descriptionShow less
A Double-Blind, Randomized, Multi-Center, Dose-Ranging, Phase 2 Study of the Efficacy and Safety of ALV-100 Versus Placebo for Maintenance of Weight Loss in Patients Previously Treated With Incretin-Based Therapies
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
Inclusion: Adult male and female participants, aged ≥18 to ≤75; BMI ≥23 kg/m2 at screening; Has been treated with incretin-based therapy for weight management at a stable dose for at least 3 continuous months prior to screening; Tolerating incretin-based therapy at the discretion of the investigator; WL of at least 10% while on incretin-based therapy and with stable BW for at least 3 months prior to screening; Willing to maintain their current general diet and physical activity regimen throughout the study.
Exclusion: Prior obesity treatment with surgery or a weight loss device; Current or history of (within 3 months prior to screening) treatment with medications that may cause significant weight gain; Lifetime history of Type 1 or Type 2 diabetes; Obesity caused by known endocrinologic disorders or by known congenital or acquired hypothalamic disease or monogenetic or syndromic forms of obesity; Family or personal history of MTC or MEN 2; Presence or history of malignant neoplasms within the past 5 years prior to screening.